Stock Scorecard



Stock Summary for Editas Medicine Inc (EDIT) - $2.14 as of 6/18/2025 9:59:16 AM EST

Total Score

8 out of 30

Safety Score

29 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for EDIT

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EDIT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EDIT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for EDIT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for EDIT (29 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for EDIT

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. 6/17/2025 2:07:00 PM
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June 6/12/2025 6:01:00 AM
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - Editas Medicine ( NASDAQ:EDIT ) 6/12/2025 6:01:00 AM
Why Is Editas ( EDIT ) Up 40% Since Last Earnings Report? 6/11/2025 3:30:00 PM
1 Stock Down 97% That Could Double, According to Wall Street 5/25/2025 10:00:00 AM
Editas Medicine: A Cautionary Tale for Investors 5/15/2025 11:30:00 PM
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June 5/14/2025 1:31:00 PM
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - Editas Medicine ( NASDAQ:EDIT ) 5/14/2025 1:31:00 PM
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line 5/14/2025 1:00:00 PM
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - Editas Medicine ( NASDAQ:EDIT ) 5/14/2025 11:01:00 AM

Financial Details for EDIT

Company Overview

Ticker EDIT
Company Name Editas Medicine Inc
Country USA
Description Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 2.14
Price 4 Years Ago 26.55
Last Day Price Updated 6/18/2025 9:59:16 AM EST
Last Day Volume 5,458,992
Average Daily Volume 2,024,250
52-Week High 6.05
52-Week Low 0.91
Last Price to 52 Week Low 135.16%

Valuation Measures

Trailing PE N/A
Industry PE 61.14
Sector PE 40.20
5-Year Average PE -3.74
Free Cash Flow Ratio 1.29
Industry Free Cash Flow Ratio 19.48
Sector Free Cash Flow Ratio 31.91
Current Ratio Most Recent Quarter 3.08
Total Cash Per Share 1.66
Book Value Per Share Most Recent Quarter 0.75
Price to Book Ratio 2.64
Industry Price to Book Ratio 18.93
Sector Price to Book Ratio 30.01
Price to Sales Ratio Twelve Trailing Months 4.60
Industry Price to Sales Ratio Twelve Trailing Months 46.63
Sector Price to Sales Ratio Twelve Trailing Months 34.69
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 83,713,000
Market Capitalization 179,145,820
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -54.74%
Reported EPS 12 Trailing Months -3.04
Reported EPS Past Year -0.92
Reported EPS Prior Year -2.88
Net Income Twelve Trailing Months -251,231,000
Net Income Past Year -237,093,000
Net Income Prior Year -153,219,000
Quarterly Revenue Growth YOY 310.40%
5-Year Revenue Growth 9.50%
Operating Margin Twelve Trailing Months -758.00%

Balance Sheet

Total Cash Most Recent Quarter 138,692,000
Total Cash Past Year 131,541,000
Total Cash Prior Year 123,652,000
Net Cash Position Most Recent Quarter 81,258,000
Net Cash Position Past Year 74,107,000
Long Term Debt Past Year 57,434,000
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 57,434,000
Equity to Debt Ratio Past Year 0.70
Equity to Debt Ratio Most Recent Quarter 0.52
Total Stockholder Equity Past Year 134,274,000
Total Stockholder Equity Prior Year 349,097,000
Total Stockholder Equity Most Recent Quarter 62,420,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -215,280,000
Free Cash Flow Per Share Twelve Trailing Months -2.57
Free Cash Flow Past Year -219,110,000
Free Cash Flow Prior Year -136,897,000

Options

Put/Call Ratio 0.01
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.14
MACD Signal 0.12
20-Day Bollinger Lower Band 0.98
20-Day Bollinger Middle Band 1.56
20-Day Bollinger Upper Band 2.15
Beta 2.10
RSI 64.75
50-Day SMA 2.49
150-Day SMA 6.91
200-Day SMA 11.84

System

Modified 6/16/2025 10:49:31 PM EST